Amneal Pharmaceuticals (AMRX) and Metsera said Tuesday that they have signed a collaboration agreement for the development and large-scale supply of new weight-loss medicines globally.
The collaboration will make Amneal Metsera's preferred supply partner in developed markets such as the US and Europe, the partners said.
The partners also said Amneal will be granted a license to commercialize Metsera's products in select emerging markets, such as India.
The collaboration requires Amneal to build two new greenfield manufacturing facilities in India. The facility for peptide synthesis and the sterile fill-finish manufacturing facility will be housed on the same site, and the project is expected to cost $150 million to $200 million over the next four to five years, the partners said. Amneal expects to break ground on the new site later this year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.